In-hospital mortality associated with community-acquired pneumonia due to methicillin-resistant Staphylococcus

Yukiyo Sakamoto1, Yasuhiro Yamauchi1, Taisuke Jo2,3

  • 1Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

BMC Pulmonary Medicine
|November 4, 2021
PubMed
Abstract

Insights

Methicillin-resistant Staphylococcus aureus (MRSA) pneumonia significantly increases in-hospital mortality and healthcare costs compared to non-MRSA pneumonia. Preventing MRSA pneumonia is crucial for better patient outcomes and reduced healthcare expenses.

Area of Science:

  • Infectious Diseases
  • Public Health
  • Health Economics

Background:

  • The comparative impact of methicillin-resistant Staphylococcus aureus (MRSA) pneumonia on patient outcomes versus non-MRSA pneumonia remains unclear.
  • This study aimed to compare in-hospital mortality and healthcare costs between MRSA and non-MRSA pneumonia patients.

Purpose of the Study:

  • To determine if MRSA pneumonia is associated with higher mortality rates than non-MRSA pneumonia.
  • To evaluate the difference in healthcare costs during hospitalization for MRSA versus non-MRSA pneumonia.

Main Methods:

  • A matched-pair cohort study utilized a Japanese national inpatient database (April 2012-March 2014).
  • Inpatients with community-acquired pneumonia were analyzed, comparing outcomes between MRSA and non-MRSA cases.
  • Multivariable regression with generalized estimating equations and multiple imputation was employed to analyze mortality and costs.

Main Results:

  • MRSA pneumonia patients (3102) showed significantly higher in-hospital mortality (adjusted OR=1.94) compared to non-MRSA pneumonia patients (12,320).
  • Hospitalization costs were substantially higher for MRSA pneumonia cases, averaging an additional USD 8502 per patient.
  • MRSA pneumonia was linked to longer hospital stays and increased healthcare expenditures.

Conclusions:

  • MRSA pneumonia is independently associated with increased in-hospital mortality.
  • Higher healthcare costs during hospitalization are a significant consequence of MRSA pneumonia.
  • Effective prevention strategies for MRSA pneumonia are essential to mitigate adverse outcomes and economic burden.